Bridgebio Pharma, Inc. · NASDAQ:BBIO

Kumar Neil sold 79,050 Bridgebio Pharma, Inc. shares (Form 4)

Traded May 7 to May 8, 2026 · Filed May 11, 2026

From May 7 to May 8, 2026, Kumar Neil (Director, Chief Executive Officer) sold 79,050 Bridgebio Pharma, Inc. shares at an average US$67.39 for US$5.33M under a trading plan, leaving 4,359,397 shares. Filed May 11, 2026 (Form 4).

Sold
79,050 shares
Price
US$67.39 average (US$66.65 to US$69.09)
Value
US$5.33M
Holding after
4,359,397 shares (held indirectly)
Trading plan
Yes (Made under a plan set in advance)
Role
Director, Chief Executive Officer

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
May 7, 2026Common StockSale11,217US$67.50584,469Indirect
May 7, 2026Common StockSale8,333US$68.38576,136Indirect
May 7, 2026Common StockSale450US$69.09575,686Indirect
May 7, 2026Common StockSale11,217US$67.494,387,230Indirect
May 7, 2026Common StockSale8,334US$68.384,378,896Indirect
May 7, 2026Common StockSale449US$69.094,378,447Indirect
May 8, 2026Common StockSale13,973US$66.65561,713Indirect
May 8, 2026Common StockSale5,077US$67.35556,636Indirect
May 8, 2026Common StockSale950US$68.35555,686Indirect
May 8, 2026Common StockSale13,974US$66.654,364,473Indirect
May 8, 2026Common StockSale5,076US$67.354,359,397Indirect

Source

View original at SEC

Related